NCT02122770View on ClinicalTrials.gov

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 1, 2014

Primary Completion Date

June 5, 2017

Study Completion Date

June 5, 2017

Conditions
Advanced Solid Tumors
Interventions
DRUG

MLN4924

MLN4924 intravenous solution.

DRUG

Fluconazole

Fluconazole tablets.

DRUG

Itraconazole

Itraconazole oral solution.

DRUG

Docetaxel

Docetaxel intravenous solution.

DRUG

Carboplatin

Carboplatin intravenous solution.

DRUG

Paclitaxel

Paclitaxel intravenous solution.

Trial Locations (4)

30322

Winship Cancer Institute at Emory University, Atlanta

37203

Sarah Cannon Cancer Center, Nashville

63110

Siteman Cancer Center - South County, St Louis

75230

Mary Crowley Medical Research Center, Dallas

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY

NCT02122770 - Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter